14.10
price up icon0.36%   0.05
after-market 시간 외 거래: 14.10
loading
전일 마감가:
$14.05
열려 있는:
$13.76
하루 거래량:
205.02K
Relative Volume:
2.25
시가총액:
$203.39M
수익:
$1.80M
순이익/손실:
$1.76B
주가수익비율:
0.1188
EPS:
118.674
순현금흐름:
$-149.23M
1주 성능:
-0.98%
1개월 성능:
+6.42%
6개월 성능:
-8.44%
1년 성능:
-59.54%
1일 변동 폭
Value
$13.53
$14.15
1주일 범위
Value
$13.51
$14.64
52주 변동 폭
Value
$10.80
$35.42

인히브릭스 Stock (INBX) Company Profile

Name
명칭
Inhibrx Biosciences Inc
Name
전화
(858) 795-4220
Name
주소
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Name
직원
161
Name
트위터
Name
다음 수익 날짜
2024-05-24
Name
최신 SEC 제출 서류
Name
INBX's Discussions on Twitter

INBX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INBX
Inhibrx Biosciences Inc
14.10 203.39M 1.80M 1.76B -149.23M 118.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

인히브릭스 Stock (INBX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-07-23 개시 JMP Securities Mkt Perform
2024-01-23 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2022-03-16 개시 SMBC Nikko Outperform
2021-09-21 개시 JMP Securities Mkt Outperform
2021-04-26 재개 Credit Suisse Outperform
2020-09-14 개시 Credit Suisse Outperform
2020-09-14 개시 Evercore ISI Outperform
모두보기

인히브릭스 주식(INBX)의 최신 뉴스

pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire

Apr 01, 2025
pulisher
Mar 26, 2025

How the (INBX) price action is used to our Advantage - Stock Traders Daily

Mar 26, 2025
pulisher
Mar 18, 2025

JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India

Mar 18, 2025
pulisher
Mar 17, 2025

Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit - Stock Titan

Mar 17, 2025
pulisher
Mar 15, 2025

Long Term Trading Analysis for (INBX) - Stock Traders Daily

Mar 15, 2025
pulisher
Mar 04, 2025

When (INBX) Moves Investors should Listen - Stock Traders Daily

Mar 04, 2025
pulisher
Feb 17, 2025

A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News

Feb 17, 2025
pulisher
Feb 11, 2025

When the Price of (INBX) Talks, People Listen - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com

Feb 05, 2025
pulisher
Jan 31, 2025

(INBX) Trading Signals - Stock Traders Daily

Jan 31, 2025
pulisher
Jan 23, 2025

Inhibrx reports promising ozekibart trial results - MSN

Jan 23, 2025
pulisher
Jan 23, 2025

Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN

Jan 23, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - Stock Titan

Jan 21, 2025
pulisher
Jan 20, 2025

How to Take Advantage of moves in (INBX) - Stock Traders Daily

Jan 20, 2025
pulisher
Jan 14, 2025

Inhibrx Biosciences enters $150M loan facility - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News

Jan 14, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - Stock Titan

Jan 13, 2025
pulisher
Jan 10, 2025

(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jan 10, 2025
pulisher
Dec 30, 2024

How To Trade (INBX) - Stock Traders Daily

Dec 30, 2024
pulisher
Dec 17, 2024

Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India

Dec 17, 2024
pulisher
Dec 09, 2024

(INBX) Trading Report - Stock Traders Daily

Dec 09, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com

Dec 05, 2024
pulisher
Dec 02, 2024

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights

Dec 02, 2024
pulisher
Nov 22, 2024

Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria

Nov 22, 2024
pulisher
Nov 18, 2024

Trend Tracker for (INBX) - Stock Traders Daily

Nov 18, 2024
pulisher
Nov 17, 2024

The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance

Nov 17, 2024
pulisher
Nov 17, 2024

institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St

Nov 17, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 14, 2024
pulisher
Nov 12, 2024

Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 09, 2024

Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com

Nov 09, 2024
pulisher
Nov 07, 2024

Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle

Nov 07, 2024
pulisher
Nov 05, 2024

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha

Nov 05, 2024
pulisher
Nov 04, 2024

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times

Nov 04, 2024
pulisher
Oct 25, 2024

James Sabry on industry-shaping changes in innovation and deal-making - BioCentury

Oct 25, 2024

인히브릭스 (INBX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):